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Abstract
Vascular calcification, which results from a process osteoblastic differentiation of vascular smooth muscle cells (VSMCs), is a
major risk factor for cardiovascular morbidity and mortality. Apelin is a recently discovered peptide that is the endogenous
ligand for the orphan G-protein-coupled receptor, APJ. Several studies have identified the protective effects of apelin on the
cardiovascular system. However, the effects and mechanisms of apelin on the osteoblastic differentiation of VSMCs have not
been elucidated. Using a culture of calcifying vascular smooth muscle cells (CVMSCs) as a model for the study of vascular
calcification, the relationship between apelin and the osteoblastic differentiation of VSMCs and the signal pathway involved
were investigated. Alkaline phosphatase (ALP) activity and osteocalcin secretion were examined in CVSMCs. The involved
signal pathway was studied using the extracellular signal-regulated kinase (ERK) inhibitor, PD98059, the phosphatidyli-
nositol 3-kinase (PI3-K) inhibitor, LY294002, and APJ siRNA. The results showed that apelin inhibited ALP activity, osteocalcin
secretion, and the formation of mineralized nodules. APJ protein was detected in CVSMCs, and apelin activated ERK and AKT
(a downstream effector of PI3-K). Suppression of APJ with siRNA abolished the apelin-induced activation of ERK and Akt.
Furthermore, inhibition of APJ expression, and the activation of ERK or PI3-K, reversed the effects of apelin on ALP activity.
These results showed that apelin inhibited the osteoblastic differentiation of CVSMCs through the APJ/ERK and APJ/PI3-K/
AKT signaling pathway. Apelin appears to play a protective role against arterial calcification.
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Introduction
Arterial calcification, which is a common disease in diabetic and
uremic patients, is associated with clinical complications, such as
myocardial infarction, impaired vascular tone, angioplasty dissec-
tion, and poor surgical outcome [1], [2]. Recent data suggest that
arterial calcifications are not a passive, degenerative, end-stage
process of vascular disease, but the result of an active, regulated
process. We and others have provided evidences that vascular
calcification resembles osteogenesis [3]–[5], and factors regulating
bone mineralization have been demonstrated in calcified plaques
[6]. VSMCs contribute significantly to the active regulation of
vascular calcification [7], [8]. However, the underlying mecha-
nisms by which vascular calcification is regulated have not been
fully understood as yet.
Apelin is a novel bioactive peptide identified as the endogenous
ligand of the orphan G protein-coupled receptor, APJ [9], [10].
Apelin is synthesized as a 77 amino acid pre-pro-peptide that can
be cleaved into fragments of different sizes that activate APJ.
Apelin-13, which is active in forms that range in length from 13–
36 residues, is the variant that is most active in signal transduction
and consequently is most frequently studied. Apelin regulates body
fluid homeostasis and cardiovascular functions through the apelin
receptor, APJ, and the level of plasma apelin markedly increases in
obesity that is associated with insulin resistance and hyperinsulin-
emia [11]–[14]. Recently, the apelin-APJ system has emerged as a
potent regulator of cardiovascular function, mediating adaptations
to physiological stress and disease. Apelin is involved in the
propagation of action potentials and contractility in cardiomyo-
cytes [15], as well as proliferation and myosin light chain
phosphorylation in VSMCs [16]–[18]. Furthermore, our recent
study demonstrated that apelin suppresses apoptosis of VSMCs
[19]. These results show that the apelin-APJ system might play an
important role in the vascular system. In a recent study, the apelin-
APJ signaling system was showed to be involved in the regulation
of aortic valve calcification [20], which is an actively regulated
pathobiological process in a similar manner to vascular calcifica-
tion. However, the effects of apelin on vascular calcification are
still not known.
In the present study, the hypothesis was tested that the apelin-
APJ signaling system is involved in the regulation of the
osteoblastic differentiation of VSMCs. To elucidate the effect of
apelin on the calcification of VSMCs and the mechanisms
involved, we used calcifying vascular smooth muscle cells
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muscle cells that can spontaneously express the osteoblastic
phenotype gene and form calcification nodules [21]. We also
examined the effect of apelin on the osteoblastic differentiation of
CVSMCs and the cell signals pathway involved. This study
provides new evidence that apelin directly modulates calcification
of CVSMCs through the APJ/ERK and APJ/PI3-K/Akt
signaling pathways, which suggests that targeting this peptide
may provide a novel therapeutic avenue by which vascular
calcification can be regulated.
Results
APJ was expressed in cultured CVSMCs
Using RT-PCR, we confirmed that APJ mRNA was expressed
in CVSMCs. APJ mRNA expression in human subcutaneous
adipose tissue was used as a positive control (Fig. 1A). The results
showed a 323 bp fragment specific to APJ. No bands were
observed in reactions without RT as template. Using Western blot
analyses, we confirmed that APJ proteins were expressed in
CVSMCs; APJ expression in human subcutaneous adipose tissue
was used as the positive control (Fig. 1). Treatment with siRNA-
APJ significantly blocked the expression of APJ protein in
CVSMCs since there were few bands detected, while no blockade
was observed on treatment with the scrambled APJ siRNA. Our
results demonstrated that CVSMCs primarily expressed APJ.
Apelin attenuated the osteoblastic differentiation and
mineralization of CVSMCs
Recent data [3]–[5] suggested that arterial calcification
resembles a bone mineralization process with expression bone-
related molecules. Alkaline phosphatase and osteocalcin are well-
established phenotypic markers of osteoblasts. We examined the
activity of ALP and osteocalcin secretion during the osteoblastic
differentiation of CVSMCs after stimulation by apelin. Treatment
with apelin for 48 h significantly inhibited ALP activity in a dose-
dependent manner. Figure 2 showed that the activity of ALP
decreased significantly (P,0.01) at 10 pM, 100 pM, 1 nM, or
10 nM concentrations of apelin (Fig. 2A). Treatment with
100 pM, 1 nM, or 10 nM apelin caused a significant dose-
dependent decrease in osteocalcin production (P,0.01; Fig. 2B).
Treatment with 1 nM apelin caused a significant decrease in the
expression of the Runx2 protein (Fig. 2D). Figure 2C shows that
10 ng/ml tumor necrosis factor-alpha (TNF-a) accelerated the
activity of ALP, and the effects were attenuated by apelin in
cultured CVSMCs (p,0.01; Fig. 2C).
Matrix mineralization, a marker for osteoblastic differentiation
and function, was assessed by the Alizarin Red S assay. Figure 3A
shows a microscopic view of the Alizarin Red S staining, where
apelin decreased mineralized nodule formation in 12 d cultures
above that seen in control cultures. Figure 3B shows an entire plate
view of the Alizarin Red S staining in 24-well plates, where
treatment with apelin exhibited decreased Alizarin Red S staining
after 12 days in culture compared to those that were not treated
with apelin. Figure 3C shows that apelin decreased the
calcification seen in CVSMCs, which was measured as CVSMCs
calcium levels.
Intracellular signaling mechanisms mediating apelin
inhibition
Mitogen-activated protein kinase (MAPK) and PI3-K/Akt play
an essential role in controlling cell differentiation. Therefore, we
determined the level of MAPK and PI3-K/Akt signaling induced
by apelin in CVSMCs. Apelin stimulated the activity of a specific
MAPK, namely ERK, in CVSMCs 5 min after incubation began,
as demonstrated by an increase in phosphorylated ERK (p-ERK)
levels; the peak activation of ERK occurred at 15 min (Fig. 4A).
Treatment with apelin also increased phosphorylated Akt (p-Akt)
levels after 5 min of incubation (Fig. 4A). The peak activation of
Akt occurred at 15 min. However, apelin had no effects on the
activation of c-jun N-terminal kinases (JNK) or p38 MAP kinases
(p38), and none of their phosphorylated forms were detected. To
exclude the false negative results, we used 50 mMH 2O2 as positive
control, which could activate p38 and JNK in calcifying vascular
cells [22].
Fig. 4B shows that the activation of ERK or Akt by apelin in
CVSMCs was inhibited by the PD98059 (ERK inhibitor) or
LY294002 (PI3-K inhibitor), respectively. Moreover, suppression
of APJ with siRNA blocked the activation of ERK and Akt
(Fig. 4C). These data indicate that apelin stimulates the ERK and
PI3-K/Akt signal transduction pathways via APJ in CVSMCs.
APJ/ERK and APJ/PI3-K/Akt signaling pathway mediated
apelin decreased osteoblastic differentiation
In order to illuminate whether APJ, ERK, and PI3-K/Akt
signaling was involved in the regulation of the osteoblastic
differentiation of CVSMCs, we used siRNA to block the
expression of APJ, and signal inhibitors to block the ERK and
PI3-K/Akt signaling pathways, respectively. Then, we observed
the activity of ALP, which was an important phenotypic marker of
osteoblastic differentiation.
Figure 5 showed that the pretreatment of cells with the ERK
inhibitor, PD98059, and the PI3-K inhibitor, LY294002, blocked
the increase in ALP activity that had been produced by 1 nM
apelin. The APJ was efficiently knocked down by RNA
interference in CVSMCs (Fig. 1). Suppression of APJ with
siRNA-APJ, but not scrambled siRNA, also abolished the
Figure 1. APJ expression in cultured CVSMCs. (A) APJ mRNA
expression in CVSMCs. Total RNA from CVSMCs was subjected to RT-
PCR. The PCR products were visualized in a 1.5% agarose gel stained
with ethidium bromide. Lane 1 human subcutaneous adipose tissue as
a positive control; Lane 2 CVSMCs; Lane 3 RNA of CVSMCs without RT as
a negative control. (B) Representative results of Western blot analysis
using an anti-APJ antibody. Total cellular protein was subjected to an
immunoblotting analysis using anti-APJ antibody. The anti-APJ
antibody identified a band at 41 kDa. Lane 1, human subcutaneous
adipose tissue as the positive control; lane 2, lysate of CVSMCs; lane 3,
lysate from CVSMCs treated with siRNA control; and lane 4, lysate from
CVSMCs treated with siRNA-APJ. b-actin was used as the loading
control.
doi:10.1371/journal.pone.0017938.g001
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indicate that the apelin-reduced osteoblastic differentiation of
CVSMCs is mediated by the APJ/ERK and APJ/PI3-K/Akt
pathways.
Discussion
The important findings of the present study were that apelin
could directly attenuate the calcificationof CVSMCsin vitro,which
provided further evidence that vascular and bone calcification share
regulatory factors. Apelin inhibited the mineralization of CVSMCs
by decreasing the activity of ALP, an enzyme that has been shown
to be important for matrix mineralization. Furthermore, apelin
inhibited the osteoblastic differentiation of CVSMCs that is
mediated by the APJ/ERK and APJ/PI3-K/Akt pathways. These
findings demonstrate that CVSMCs can be direct targets of apelin.
Arterial calcification is an actively regulated process, which is
similar to osteogenesis [23], [24]. The trans-differentiation process
of VSMCs to the osteogenic phenotype plays a crucial role in the
formation of arterial calcification. Calcifying vascular cells, a
Figure 2. Effects of apelin on ALP activity, osteocalcin secretion and Runx2 protein expression in cultured CVSMCs. Cells were treated
with vehicle (serum-free medium) or apelin at 10 pM, 100 pM, 1 nM, or 10 nM for 48 h in serum-free DMEM. ALP activity and osteocalcin secretion
were determined and normalized to the total cell protein. (A) The dose response of apelin on ALP activity in cultured CVSMCs. (B) The dose response
of apelin on osteocalcin secretion. The group results are shown. (C) The dose response of apelin on ALP activity with control (no TNF-a) or medium
containing 10 ng/ml TNF-a in cultured CVSMCs. The bars represent mean 6 SD (
##P,0.01 vs. control; **P,0.01 compared with CVSMCs given TNF-a
induction without apelin, n=3). (D) Cells were treated with vehicle (serum-free medium) or apelin at 1 nM for 48 h in serum-free DMEM. Total cellular
protein was subjected to immunoblotting analysis using anti-RUNX2 and anti-b-actin antibody.
doi:10.1371/journal.pone.0017938.g002
Apelin Attenuates VSMCs Calcification
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17938subpopulation of cells from the VSMCs that have the ability to
spontaneously undergo osteoblastic differentiation and minerali-
zation [5], is a very useful cell model for the analysis of the
mechanisms of arterial calcification; this has been used in several
studies [21], [25], [26]. Here, we employed CVSMCs to reveal the
relationship between apelin and arterial calcification.
Apelin was found in 1998 to be an endogenous ligand of the
human orphan G protein-coupled receptor, APJ, which
previously had been identified by the Human Genome Project
in 1993 as a member of the superfamily of 7-transmembrane G-
protein coupled receptors [9], [10]. Apelin peptides have been
shown to affect many biological functions in mammals,
including the neuroendocrine, cardiovascular, and immune
systems [27]. Apelin and APJ are widely expressed throughout
the body [28]–[31]. In vascular system, apelin and APJ are
k n o w nt ob ee x p r e s s e di nt h ee n d o t h e l i u ma n dV S M C s[ 3 2 ] ,
[33], which indicates a paracrine or autocrine mode of action in
the vascular system. Recently, Hashimoto et al. reported that
apelin induces the phosphorylation of the myosin light chain,
which is a major regulatory eventi ni n i t i a t i n gs m o o t hm u s c l e
Figure 3. The effects of apelin on the mineralization of the matrix in cultured CVSMCs. (A) A representative microscopic view of the
Alizarin Red S staining at a magnification of 4006for control cells and cells treated with 1 nM apelin in cultures of 12 d duration. (B) A representative
entire plate view of the Alizarin Red S staining in 24-well plates for control cells and cells treated with apelin in 12 d cultures. (C) Quantification of the
calcium content of the cell layers as measured by the atomic absorption spectroscopy method and normalized to the cellular protein content. The
bars represent the mean 6 SD (n=3; **P,0.01 vs. control).
doi:10.1371/journal.pone.0017938.g003
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proliferation of VSMCs, which indicates a possible function
role for apelin in vascular function. Some experiments have
shown that apelin elicits endothelium-dependent, nitric oxide-
mediated vasorelaxation and reduces arterial blood pressure
[34], [35], as well as endothelium-independent vasoconstriction,
by acting directly on VSMCs [36]. In addition, apelin
demonstrates potent and long-lasting positive inotropic activity,
which is preserved even in injured myocardium and is not
accompanied by myocardial hypertrophy [37], [38]. These
results indicate that apelin has a protective effect on the
cardiovascular system.
Our previous study demonstrated that apelin inhibited the
apoptosis of VSMCs through the APJ/PI3-K/Akt pathway [19].
However, the effect of apelin on osteoblastic differentiation by
VSMCs is still unknown. Using RT-PCR and immunoblotting, we
identified CVSMCs that primarily expressed APJ and were a
target for the action of apelin. Our data showed that apelin
decreased the activity of ALP and osteocalcin secretion, which are
well-recognized as early markers of osteoblastic differentiation and
increase during the differentiation of CVSMCs. Meanwhile, apelin
directly inhibited the formation of mineralized nodules. We also
showed that TNF-a increased the activity of ALP, and this effect
was attenuated by apelin treatment in cultured CVSMCs. These
Figure 4. Effects of apelin on MAKP and PI3-K/Akt activation in CVSMCs. Cell lysates were subjected to Western blotting and incubated
with antibodies against p-ERK, ERK, p-P38, P38, p-JNK, JNK, p-Akt, and Akt. The representative results are shown. (A) Cells exposed to 1 nM apelin for
5–60 min, or 50 mMH 2O2 for 15 min as a positive control for P38 and JNK activation. (B) Cells incubated with PD98059 (10 mM) or LY294002 (10 mM)
for 2 h prior to treatment with 1 nM apelin for 15 min. (C) Cells treated with scrambled APJ siRNA or APJ siRNA in the presence of 1 nM apelin.
doi:10.1371/journal.pone.0017938.g004
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apelin had no effect on the activity of ALP in human osteoblasts
[39]. We speculate that this might be a result of the use of different
kinds of cells used in each study. Our present study also
demonstrated apelin decreased the expression of Runx2 in
CVSMCs, which is an important osteoblast differentiation
transcription factor. These results suggest apelin inhibit osteoblas-
tic differentiation of CVSMCs.
Several cytokines [40]–[46] have been identified as playing
biphasic effects on the osteoblastic differentiation of VSMCs and
osteoblast differentiation. For example, adiponectin could increase
osteoblast differentiation [41], [47] and decrease the osteoblastic
differentiation of VSMCs [21]. Furthermore, vascular calcification
is frequently accompanied by decreased bone mineral density or
disturbed bone disease. This contradictory association, which has
been observed mainly in osteoporosis and chronic kidney disease,
is called the ‘calcification paradox’ [48]. Here, our present data
demonstrated that apelin directly inhibited the osteoblastic
differentiation of CVSMCs.
To gain further insight into the mechanism by which apelin
inhibited the osteoblastic differentiation of CVSMCs, we evalu-
ated signaling pathway events. MAPK and PI3-K/Akt are well
known to play essential roles in controlling cell differentiation
[49]–[51]. Our study showed that apelin induced the activation of
ERK and Akt in CVSMCs. Treatment with the PI3-K inhibitor,
LY294002, abolished the activation of Akt in human VSMCs,
which indicated that the phosphorylation of Akt is dependent on
PI3-K. The suppression of APJ with siRNA blocked the effects of
apelin on ERK and Akt, which suggested that the activation of
ERK and PI3-K/Akt was mediated through APJ. Furthermore,
the inhibition of APJ expression, PI3-K/Akt activation, or ERK
activation, blocked effects of apelin on decreasing the activity of
ALP. This indicates that apelin inhibits the osteoblastic differen-
tiation of CVSMCs through the APJ/ERK and APJ/PI3-K/Akt
signaling pathways.
Other studies as well as our previous experiments demonstrated
that apelin activates the ERK and PI3-K/Akt pathways [19], [52].
These stimulations are generally recognized as characteristic of
cardioprotective agents. Several studies [6], [53], [54] have
indicated that PI3-K/Akt activation inhibited the osteoblastic
differentiation of VSMCs, and the results of our present
experiment supported this conclusion. The relationship between
ERK activation and osteoblastic of VSMCs is still controversial.
Several studies have shown that ERK activation might obscure the
osteoblastic differentiation of VSMCs [4], [55], and others results
have been inconsistent with these [55]–[57]. Meanwhile, other
experiments have concluded that ERK activation had no effect on
the osteoblastic differentiation of VSMCs [58]. Our present study
also showed that the ERK inhibitor, PD98059, attenuated the
activity of ALP that had been decreased by apelin. It is necessary
Figure 5. ERK and PI3-K signaling pathways mediated the apelin-induced osteoblastic differentiation of CVSMCs. Cell were incubated
with PD98059 (10 mM) or LY 294002 (10 mM) for 2 h prior to treatment with 1 nM apelin. Cells were also treated with the siRNA control or siRNA-APJ
in the presence of 1 nM apelin. ALP activity was measured, normalized to the total cellular protein contents. The bars represent the mean 6 SD (n=3;
**P,0.01 vs. control).
doi:10.1371/journal.pone.0017938.g005
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blastic differentiation of VSMCs should be thoroughly investigat-
ed.
Our findings suggest a crucial role for apelin in decreasing the
osteoblastic differentiation of VSMCs, and the APJ/ERK and
APJ/PI3-K/Akt is implicated as being involved in this effect. This
suggests that apelin plays a protective role against arterial
calcification.
Materials and Methods
Reagents
Synthetic apelin-13 peptide was purchased from the American
Peptide Company Inc. (Sunnyvale, CA, USA). The amino acid
sequence of apelin-13 is Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-
Pro-Met-Pro-Phe. Recombinant human IGF-I protein was
purchased from PEPROTECH (London, UK). Anti-human
RUNX2 (also called cbfa1, PEBP2aA) antibody, anti-extracellular
signal-regulated kinase (ERK), p-ERK, p-p38, p38, c-jun N-
terminal kinase (JNK), p-JNK, Akt, p-Akt antibody, anti-mouse,
and rabbit IgG peroxidase conjugate antibodies were purchased
from Santa Cruz Biotechnology Inc (Waltham, MA, USA). Anti-
human apelin receptor (APJ) antibody was purchased from Abcam
Inc. (Cambridge, MA, USA). Anti-b-actin polyclonal antibody was
purchased from Sigma (St. Louis, MO, USA). PD98059 and
LY294002 were purchased from Calbiochem Corp. (San Diego,
CA, USA).
Cell culture and in vitro calcification
Human calcifying vascular smooth muscle cells (CVSMCs) from
excess donor vasculature after kidney transplantations were grown
from explants of normal arterial tissues, and approved by the
Ethics Committee of the Second Xiangya Hospital of Central
South University, China. Written informed consent was obtained
from each participant. The cells were cultivated as we have
previously described [21], and experiments were performed
between passages 3 and 6 from the primary culture. Briefly, the
arterial tissues were removed under sterile conditions. After the
arterial tissues were rinsed several times in Hanks’s balanced salt
solution, the adventitia was removed; the remaining arterial tissues
were minced and digested in 5 ml of digestion solution (0.125 mg/
ml elastase, 0.25 mg/ml soybean trypsin inhibitor, 10 mg/ml
collagenase I, 2.0 mg/ml crystallized bovine albumin, and 15 mM
HEPES) at 37uC for 45 min. The cellular digests were filtered
through a sterile 100-mM nylon mesh, centrifuged at 1,000 rpm
for 10 min, and washed twice in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% FBS (Gibco-BRL) before
culture in the same medium. CVSMCs were isolated from
cultures in which multicellular nodules spontaneously appeared.
From these nodule-forming cultures, cells were cloned by limiting
dilution and single cell harvesting. Colonial lines were identified as
CVSMCs by their positive staining with monoclonal antibody a-
actin and by their ability to express high levels of ALP and form
calcified nodules.
Adipose tissue
Subcutaneous adipose tissue was obtained from patients who
had undergone mammoplastic surgery. Samples were snap-frozen
and stored in liquid nitrogen until the extraction of proteins.
Detection of APJ gene expression in cultured CVSMCs by
RT-PCR
To investigate the expression of APJ mRNA in CVSMCs,
reverse transcription polymerase chain reaction (RT-PCR) was
performed as our previous described [39]. Total RNA from
cultured CVSMCs and subcutaneous adipose tissue was isolated
using Trizol reagent (Gibco) according to the manufacturer’s
recommended protocol. There is only 1 exon and 1 gene found in
the APJ genomic region spanning 4535 bp. We could not obtain
intron-spanning primers for APJ, therefore we performed DNase I
digestion of isolated total RNA from cultured CVSMCs and
subcutaneous adipose, to ensure no genomic contamination. The
PCR primers were 59cacctggtgaagacgctgta 39 and 59 taggggatg-
gatttctcgtg yielding a 323 bp fragment. CVSMCs RNA without
RT as negative control was included. RT was performed using
1.0 mg total RNA and the Reverse Transcription System
(Promega, Madison, WI, USA). PCR was performed as follows:
94uC for 1 min, 58uC for 45 s, and 72uC for 1 min for 35cycles
followed by a 10 min incubation at 72uC. Ten microliters of the
reaction mixture was electrophoresed on 1.5% agarose gels and
stained with ethidium bromide to verify bands. The identities of
PCR products were confirmed by direct sequencing using an
automatic DNA sequencer (PE Applied Biosystems).
Detection of APJ in cultured CVSMCs by immunoblotting
analyses
To investigate the expression of APJ protein in CVSMCs, the
cell layers were homogenized with Triton lysis buffer (50 mM
Tris-HCl, pH 8.0, containing 150 mM NaCl, 1% Triton X-100,
0.02% sodium azide, 10 mM EDTA, 10 mg/ml aprotinin, and
1 mg/ml aminoethylbenzenesulfonyl fluoride). Homogenized
protein (50 mg) was loaded onto a 7.5% polyacrylamide gel.
After electrophoresis, the SDS-PAGE-separated proteins were
transferred onto a nitrocellulose membrane (Amersham Pharma-
cia Biotech). The membrane was blocked with 2.5% nonfat milk in
PBS and incubated with anti-mouse APJ in PBS for 2 h. The
membrane was reprobed with rabbit anti-mouse IgG conjugated
with horseradish peroxidase for 1 h. Blots were processed using an
ECL kit (Santa Cruz) and exposed to the film. The same
membrane was stripped and reprobed with anti-b-actin antibody
as a loading control.
Analysis of alkaline phosphatase activity and osteocalcin
secretion in cultured CVSMCs
Calcifying CVSMCs were washed three times with PBS,
scraped into 1 ml of 10 mM Tris-Cl buffer (pH 7.6) that
contained 0.1% Triton-X-100 on ice, and centrifuged. The lysates
were homogenized. Then, ALP activity was assayed by the
spectrophotometric measurement of p-nitrophenol release at
37uC. ALP activity was normalized to the total protein content
of the cell layer. Osteocalcin released into the culture media was
measured using a specific radioimmunoassay kit (DiaSorin,
Stillwater, MN, USA). To normalize protein expression to the
total cellular protein, a fraction of the lysate solution was used in a
Bradford protein assay.
Measurement of mineralized matrix formation
For Alizarin Red S staining, CVSMCs in 24-well plates were
cultured in medium that contained either 1 nM apelin or vehicle
for 12 days. Then, the extent of mineralized matrix was
determined by Alizarin Red S staining [59]. Briefly, cells were
fixed in 70% ethanol for 1 h at room temperature and stained with
40 mM Alizarin Red S for 10 min. Next, cell preparations were
washed with PBS to eliminate nonspecific staining. The stained
matrix was assessed using a Nikon Diaphot inverted microscope
and samples were photographed using a Nikon 35-mm camera
(Nikon, Tokyo, Japan).
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PBS and decalcified with 0.6 N HCl for 24 h, Calcium content
was determined by measuring the concentrations of calcium in the
HCl supernatant by atomic absorption spectroscopy. After
decalcification, the cells were washed three times with PBS and
the cells were solubilized with 0.1 N NaOH/0.1% SDS. The
protein content was measured with a Bradford protein assay. The
calcium content of the cell layer was normalized to the protein
content.
RNA interference against APJ
Two pairs of small-interfering RNAs (siRNAs) and control
siRNAs were synthesized by Genesil Biotechnology Co. (Wuhan,
China) as previously described [39]. The targets were GGUG-
CAGUGCUACAUGGACdTdT (for human APJ siRNA) and
AUGCUGCGAGCUAGAUCGGdTdT (for scrambled human
APJ siRNA). For gene knockdown experiments, CVSMCs were
plated into 60-mm-diameter dishes and cultured for 24 h in
medium without antibiotics. Cells were transfected with siRNAs
(1 nmol per well) using Lipofectamine 2000 (Invitrogen Inc.
Carlsbad, CA, USA) according to the instructions of the
manufacturer. After 24 h of culture, cells were retransfected with
siRNAs or controls and then recultured for another 48 h. Protein
expression was analyzed by Western blotting.
Detection of MAPK and PI3-K/Akt activation by Western
blot analysis
CVSMCs were initially treated with 1 nM apelin for between
5–60 min. Then, cellular monolayers were washed quickly with
cold PBS that contained 5 mM of EDTA and 0.1 mM Na3VO4,
and lysed with a lysis buffer that consisted of 20 mM Tris–HCl
(pH 7.5), 150 mM NaCl, 1% Triton X-100, 10 mM of NaH2PO4,
10% glycerol, 2 mM Na3VO4, 10 mM NaF, 1 mM ABSF,
10 mg/ml leupeptin and 10 mg/ml aprotinin. Western blotting
was performed as described above. Proteins were then transferred
to a nitrocellulose membrane. The membrane was incubated with
anti-p-p38, -p38, -p-ERK, -ERK, -p-JNK, -JNK, -p-Akt and -Akt
primary antibodies at 1:500 in PBS for 2 h. The membranes were
then incubated with goat anti-mouse or rabbit IgG antibody
conjugated with horseradish peroxidase at 1:1000 in PBS for 1 h.
Blots were processed using an ECL Kit (Santa Cruz) and exposed
to X-ray film.
Detection of signaling pathways involved in the apelin-
attenuated osteoblastic differentiation of CVSMCs
To determine the downstream intracellular signaling pathways
affected by apelin treatment, we explored the relationship between
extracellular signal-regulated kinases (ERK) and PI3-K phosphor-
ylation of CVSMCs and treatment with apelin. CVSMCs were
pretreated with 10 mM PD98059 (an ERK inhibitor) or 10 mM
LY294002 (a PI3-K inhibitor) for 2 h prior to apelin treatment.
ALP activities were assessed after 48 h.
Statistical analyses
The results of the experiments were normalized relative to total
protein levels, as determined by Bradford’s method. The data are
expressed as means 6 standard deviation (SD). Comparisons
between values of more than two groups were performed by an
analysis of variance (one-way ANOVA). P-values of less than 0.05
were considered to be statistically significant in all cases. All
experiments were repeated at least three times, and representative
experiments are shown in the Figures.
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